Research programme: selective alpha-1A adrenoceptor antagonists - Lundbeck

Drug Profile

Research programme: selective alpha-1A adrenoceptor antagonists - Lundbeck

Alternative Names: Alpha 1A adrenoceptor antagonists research programme - Lundbeck

Latest Information Update: 31 Mar 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Lundbeck Research USA
  • Developer Johnson & Johnson Pharmaceutical Research & Development LLC; Lundbeck Research USA; Sun Pharmaceutical Industries
  • Class
  • Mechanism of Action Alpha 1a adrenergic-receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Benign prostatic hyperplasia

Most Recent Events

  • 25 Mar 2015 Sun Pharmaceutical Industries acquires Ranbaxy
  • 06 Mar 2003 Synaptic Pharmaceutical has been acquired by Lundbeck A/S
  • 11 Jul 2002 Synpatic's alpha1A receptor antagonists have been licensed to Ranbaxy in India
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top